Management of Indolent Lymphomas
2025-05-08 19:00 - 20:30 (Africa/Nairobi)
Moderator: Prof Nicholas Otieno Abinya
Speakers & Topics:

Dr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration
Prof Shahin Sayed: Histopathology & Low‑Grade Lymphomas
Dr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach

Dr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.
– Key clinical points:
• CLL is heterogeneous and often indolent; many patients start with watchful waiting.
• Symptomatic cytopenias and disease progression warrant treatment.
• Therapy included bendamustine, rituximab, venetoclax, and novel agents like ibrutinib.
– Highlighted diagnostic limitations due to access to FISH, molecular testing, and cost of targeted therapies.
– Underscored importance of tailored care, especially in young patients and those with co-morbidities.
Dr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas, which are slow-growing B-cell neoplasms such as CLL/SLL, follicular lymphoma, and MZL.
– Emphasized the necessity for clinical vigilance and long-term monitoring.
– Stressed the need for diagnostic precision, the role of immunophenotyping, and the heterogeneity of clinical presentations.
– Highlighted treatment considerations: watchful waiting, targeted therapy, and challenges in resource-limited settings.
Prof. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas, emphasizing pathology-driven subtypes.
– Covered key immunophenotypic markers: CD5, CD23, LEF1, BCL2, Cyclin D1, etc.
– Presented rare pediatric and adolescent cases, illustrating diagnostic complexity and variability.
– Detailed histologic signs of aggressive transformation (e.g. high Ki-67, prolymphocytic features).
– Outlined molecular diagnostics: del(11q, 13q, 17p), TP53 mutations, IGHV SHM – all important for prognosis and treatment.
– Discussed evolving terminology: classic FL, follicular lymphoma with uncommon features (uFL), and follicular large cell lymphoma.

Melanoma/Skin Cancer
2025-05-14 19:00 - 20:30

Bladder Cancer
2025-05-15 19:00 - 20:30
Moderator: Roselyne A. Okumu
Speakers & Topics:

Dr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer
Prof Peter Mungai: Superficial Bladder Cancer Management

Management of Non-Muscle-Invasive Bladder Cancer (NMIBC)
– NMIBC represents ~75% of new bladder cancer cases, typically presenting with painless hematuria.
– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.
– Risk-based treatment approach:
• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)
• High-risk: 6-week BCG induction ± maintenance
– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.
– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).
– Trials (MoonRISe-3, SunRISe-5) show >80% DFS in high-risk patients.
Updates in Advanced and Metastatic Bladder Cancer
– Bladder cancer is the 4th most common male cancer globally.
– Molecular profiling is critical: test for FGFR3 and HER2.
– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).
– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.
– 2nd/3rd-line: Erdafitinib (FGFR+), T-DXd (HER2+).
– Novel ADCs (Enfortumab, Sacituzumab) offer superior outcomes to chemo.
– Trial enrolment is encouraged for all patients.
Key Clinical Takeaways
– Intravesical innovation is changing NMIBC treatment beyond BCG.
– Biomarker-driven therapy is now essential for managing advanced bladder cancer.
– Routine molecular testing is critical for individualized care

Multidisciplinary Approaches to Paediatric Brain Tumours
2025-05-22 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Dr Alfred Odhiambo
Speakers & Topics:

Mr David L. Oluoch‑Olunya: Surgical Management of Paediatric Brain Tumours
Dr Michael Magoha: Endocrinological Management of Paediatric Brain Tumours
Dr Ahmed Korir: Radiation Therapy in Paediatric Brain Tumours

Mr. David Oluoch-Olunya presentation summary
– Over 25 years, Kenya has moved from fragmented care to growing multidisciplinary tumour boards in urban centres.
– Key challenges remain: late diagnosis, radiotherapy access disparities, and poor survivorship follow-up.
– Regional initiatives like the Brain Tumor Consortium of Africa (BTCoA) aim to standardize care and improve data sharing.
– Priorities: expand MDT care to counties, national paediatric tumour registry, survivorship and rehab programs.
– Kenya has made major strides, but gaps persist in early detection, diagnostics, and referral systems.
Dr Ahmed Komen’s presentation summary
– RT use depends on age, tumour type/location, other treatments, and disease extent.
– Modern RT techniques include 2D, 3DCRT, IMRT, VMAT, and proton therapy (where available).
– RT aims: radical (curative) or palliative (symptom relief).
– RT delivery to children requires precise planning and often sedation or anaesthesia.
– Late effects of RT: cognitive decline, growth delay, hearing loss, hormonal dysfunction, secondary cancers.
– Younger age (<7 yrs) and higher doses correlate with greater neurocognitive risks.
– Proton therapy offers tissue-sparing benefits but has limited availability in LMICs.

EA Oncology Summit
2025-05-24 08:30 - 16:00 | Virtual Event (Zoom), Kenya
Loading Viewer...

Brain Cancer / Brain Tumour
2025-05-28 19:00 - 20:30

Cancer Survivorship
2025-06-04 19:00 - 20:30

Cancer Survivor's Day
2025-06-05 19:00 - 20:30
Moderator: Prof John Weru
Speakers & Topics:

Muthoni Mate: Tokenism in Cancer Survivor Involvement – Beyond Being the Face on a Brochure
Dr Mary Nyangasi: Beyond Remission – Best Practices in Survivorship Care Planning & Patient Navigation
Dr Esther Muinga: Palliative Care as a Pillar of Survivorship

Muthoni Mate highlighted the issue of tokenism where survivors are symbolically included without influence. She called for shifting from consultation to co-design and recognizing survivors as experts by experience. Obstacles include medical jargon, lack of trauma-informed engagement, minimal institutional support, and preference for academic voices. True engagement must be collaborative, compensated, and empowering, allowing survivors to shape policy and practice. She urged stakeholders to move beyond the ‘face on the brochure’ and include survivors meaningfully in healthcare decision-making.
Dr. Nyangasi emphasized the critical role of survivorship care planning and patient navigation in ensuring long-term quality of life for cancer survivors. She outlined survivorship as a continuum beginning at diagnosis, extending beyond acute care into surveillance, psychosocial support, and lifestyle guidance. Evidence from over 60 systematic reviews shows that patient navigation improves care access, adherence to follow-up, and satisfaction. Barriers in Kenya include weak health systems, low awareness, lack of funding, and absence of integrated care protocols. There is urgent need for structured survivorship models and investment in navigation programs with proven return on investment.
Dr. Muinga presented palliative care as integral to survivorship, aiming to improve quality of life through pain control, emotional support, and end-of-life care. She emphasized the interconnectedness of palliation, prevention, and health promotion. Effective survivorship care requires collaboration across disciplines and includes surveillance, psychosocial screening, and health education. Survivorship plans should empower patients and caregivers, incorporate national policies, and address financial and cultural challenges. She concluded that palliative care is not about dying—it’s about living fully post-treatment.

Palliative Care: Integrative Oncology
2025-06-11 19:00 - 20:30

Clinical Nutrition in Cancer
2025-06-12 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Dr Catherine Nyongesa
Speakers & Topics:

Kennedy Okinda: Medical Nutrition Therapy Cases in Cancer Care – A Cross‑Sector Lens
Traceyann Njeri Wacheke: Medical Nutrition Therapy in Survivorship & Secondary Cancer Prevention

Cancer and Nutrition
2025-06-18 19:00 - 20:30

Sickle Cell Disease
2025-06-19 19:00 - 20:30
Date: 19 June 2025 | Time: 7:00 – 8:30 PM EAT
Moderator: Dr Peter Oyiro
Prof. Jessie Githang’a – Sickle Cell Clinical Trials in Kenya
Prof. Jessie Githang’a emphasized the need for more SCD clinical trials in Africa, where the disease burden is greatest. She outlined the underrepresentation of African populations in global trials and highlighted the benefits of local research, including better understanding of drug efficacy, safety, and socio-genetic differences. She discussed ongoing and past trials in Kenya involving Hydroxyurea, Crizanlizumab, and gene therapies, noting challenges like infrastructure gaps and limited expertise. Prof. Githang’a called for improved research capacity, team collaboration, and greater engagement with trial participants.
Dr. Doreen Mutua – Management of SCD in the 21st Century
Dr. Doreen Mutua reviewed modern SCD management, highlighting the importance of early diagnosis, health maintenance, and Hydroxyurea therapy. She addressed common complications like stroke, chronic pain, and organ damage, and emphasized early intervention to prevent progression. Transition of care for adolescents, genetic counseling, and curative options such as HSCT and gene editing were also discussed. Her presentation underscored the need for advocacy, access to comprehensive care, and integration of newborn screening into national systems.

Sickle Cell Disease
2025-06-25 19:00 - 20:30

Lymphoma Management in Africa
2025-07-03 19:00 - 20:30
Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT
Moderator: Dr Beatrice Jepngetich
Dr. Anne Mwirigi – Relapsed/Refractory DLBCL
Dr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring, interim PET imaging, and molecular markers to identify high-risk individuals. For chemosensitive relapses, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy, accelerating cellular therapy referral in primary-progressive cases, and advocating for regional access programs to overcome cost barriers.
Dr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities
Dr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification, Hans/Choi cell-of-origin algorithms, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials, ensuring truly personalized care for aggressive lymphoma in African settings.

Prostate Cancer
2025-07-10 19:00 - 20:30
Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT
Moderator: Dr Ahmed Komen
Dr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer
Dr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection), first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations), radiotherapy for low‑volume disease, and the sequencing of novel agents (second‑generation antiandrogens, PARP inhibitors, radioligand therapy) in castration‑resistant settings, alongside essential supportive measures (bone protection, multidisciplinary review).
Dr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer
About 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes), prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels, variant classification (pathogenic, VUS), genetic counseling, cascade testing for relatives, and periodic reclassification to inform personalized therapy and family risk management.
Dr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors
PARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP, PROfound, TRITON3, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms.

Endometrial Cancer
2025-07-17 19:00 - 20:30
Moderator: Dr Anisa Mburu
1. Dr. Caroline Tonio – Advanced Endometrial Cancer
Dr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease, treatment has evolved from conventional chemotherapy to biomarker-driven strategies.
Molecular subtyping, as identified by the TCGA, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment.
2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging
Dr. Warfa provided an overview of the pathology, risk factors, and staging of endometrial cancer. Most cases occur in postmenopausal women, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure, obesity, and genetic syndromes.
Diagnosis relies on biopsy and imaging. Pathologically, cancers are divided into Type I and II, with molecular subtypes (e.g., POLE, dMMR, p53-abn) offering greater prognostic value.
Standard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.

Sarcoma Care
2025-07-24 19:00 - 20:30
Bridging Gaps in Soft Tissue Sarcoma Care
Date: 24 July 2025 | 7:00 – 8:30pm EAT
Moderator: Dr Rose Munge
Dr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa
Soft tissue sarcomas are rare malignant tumors of mesenchymal origin, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm), high recurrence (78%), and better outcomes with radical excisions.
Chemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However, access to radiotherapy remains limited, impacting outcomes. Timely radiotherapy, as seen in Tanzania, improves survival.
Key gaps include limited resources, lack of local treatment guidelines, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers, local research, and developing Africa-specific management guidelines.

Bone Marrow Transplant
2025-07-31 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Date: 31 July 2025 | 7:00 – 8:30PM EAT
Moderator: Dr Matilda Ongondi
Dr. Rohini Radia – Bone Marrow Transplantation
Bone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up.
There are two main types:
Autologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD), infections, and infertility, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas.
Patient and donor selection, conditioning protocols, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential, especially due to chronic GVHD and relapse risks. In sickle cell disease, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration.
Success in BMT depends on early identification, thorough preparation, and sustained multidisciplinary care beyond the immediate post-transplant period.

Cervical Cancer
2025-08-07 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Speakers:

Dr. Dulcie Wanda

Clinical & Radiation Oncologist
Head of Department, Nakuru Regional Cancer Treatment Centre

Topic: Radiotherapy in Management of Advanced Cancer of the Cervix.
2. Dr. Edward Sang

Gynaecologist and Oncologist, MP Shah Doctors Plaza, Nairobi

Topic: Surgical Techniques in Cervical Cancer
Moderator:
Dr. Afrin Fatima Shaffi

Gynecologic Oncologist, Nairobi West Hospital

Cancer Care
2025-08-28 19:00 - 19:30
Moderator:

Dr. Anne Mwirigi – Consultant Haematologist & Assistant Professor, Aga Khan University Hospital, Nairobi

Speakers:

Dr. Arjun Ghosh – Consultant Cardiologist, Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London & University College London Hospital
Dr. Manel Haj Mansour – Consultant Medical Oncologist & Section Head of Medical Oncology, Aga Khan University Hospital, Nairobi
Dr. Charles Kariuki – Interventional Cardiologist, Ubora Heart, The Nairobi Hospital
Dr. Gladwell Kiarie – Medical Oncologist, The Nairobi Hospital

Paediatric Bone Marrow Transplantation
2025-09-04 19:00 - 20:30
Date & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT)
Moderator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist,MP Shah Hospital, Nairobi
Speaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist,Gertrude’s Children’s Hospital, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities

Palliative Support and Pain Management
2025-09-11 19:00 - 20:30
Moderator:

Dr. Zipporah Ali – Palliative Care Physician and Public Health Specialist

Speakers:

Dr. Lee Ngugi – Pain Management Specialist, Anaesthesiologist & Lecturer, Kenyatta University, School of Medicine, NairobiTopic: Interventional Pain Management Procedures in Cancer-Related Pain
Dr. Esther Munyoro – Neuro-anaesthetist & Palliative Care Specialist, Former Head of Pain and Palliative Care Unit, Kenyatta National Hospital, NairobiTopic: Palliative care: Making it real

Management of CML Blast Crisis
2025-09-18 19:00 - 20:30
MANAGEMENT OF CML Blast Crisis
📅 Date: 18th September 2025⏰ Time: 7 PM – 8:30 PM EAT
MODERATORDr. Angela McligeyoPhysician and Medical Oncologist
SPEAKERProfessor Gianantonio RostiIRCCS IRST “Dino Amadori”, Meldola (Italy)Managing CML in Blast Crisis When Intensive Treatment Options are Available
SPEAKERProfessor Malkit RiyatAssociate Professor of Haematology & Consultant Haematologist, Aga Khan University Hospital, NairobiManaging CML in Blast Crisis When Intensive Treatment Options are Limited

Prostate Cancer Awareness
2025-09-25 19:00 - 20:30
Theme: Advancing Prostate Cancer Awareness
Date: 25th September 2025
Time: 7 PM – 8:30 PM EAT

Moderator: Prof. Mungai Ngugi (Consultant Urologist & Transplant Surgeon, Upper Hill Medical Center & Director, East Africa Kidney Institute)
Speakers:

H.E. Prof. Peter Anyang’ Nyong’o (Governor, Kisumu County)
Dr. Amina K. Habib (Medical Oncologist, Aga Khan University Hospital, Nairobi)
Prof. Nicholas Othieno Abinya (Professor of Medicine, Medical Oncologist, The Nairobi Hospital)

Organizers/Sponsors:

Kenya Society of Haematology & Oncology (KESHO)

Triple Negative Breast Cancer
2025-10-02 19:00 - 20:30
Triple Negative Breast Cancer: Early and Late Stage Management(CPD Accredited)
Date & Time:

2nd October 2025
7 PM – 8:30 PM (EAT)

Speaker: Dr. Joseph AbuodhaConsultant Medical Oncologist, Department of Haematology and Oncology, Aga Khan University Hospital, NairobiTopic: Triple-Negative Breast Cancer: Advancing Care Across Early and Late Stages
Moderator: Dr. Helena MusauConsultant Clinical/Radiation Oncologist and Palliative Care Specialist
Summary:
Triple-Negative Breast Cancer: Contemporary Clinical Updates
Presentation by Dr Joseph Abuodha

Dr Joseph Abuodha, Consultant Medical Oncologist, delivered a comprehensive clinical update on the biology, diagnosis and management of triple-negative breast cancer (TNBC), highlighting its aggressive nature, molecular heterogeneity and disproportionate burden in African populations.
The presentation outlined the distinctive pathological and molecular characteristics of TNBC, emphasizing the absence of hormone receptor and HER2 expression, high-grade histology and frequent genomic instability. Local and global epidemiological data were reviewed, underscoring the higher prevalence and mortality associated with TNBC in African and African-descended populations.
Management strategies across the disease spectrum were discussed, with chemotherapy reaffirmed as the backbone of treatment in non-metastatic disease. Dr Abuodha highlighted the growing role of neoadjuvant therapy, particularly for stage II and III disease, noting that achievement of pathologic complete response (pCR) remains a critical prognostic marker. Evidence supporting the incorporation of platinum agents and immune checkpoint inhibitors in selected patients was reviewed, alongside adjuvant strategies for residual disease, including capecitabine and PARP inhibitors in BRCA-mutated cancers.
In the metastatic setting, the importance of repeat biopsy and molecular reassessment was emphasized to guide therapy. Emerging systemic options including immunotherapy, PARP inhibitors and antibody–drug conjugates were discussed in the context of treatment sequencing and patient selection, alongside the central role of supportive and palliative care.
Key takeaway: Triple-negative breast cancer requires a biologically informed, stage-adapted treatment approach, with increasing emphasis on neoadjuvant strategies, molecular testing and integration of novel systemic therapies to improve outcomes in high-risk populations.

Advancing Care in HER2 Positive Breast Cancer
2025-10-15 08:00 - 17:00
Date: 9th October 2025
Time: 7 PM – 8:30 PM (EAT)CPD Accredited

Speakers

Dr. Manel Haj MansourConsultant Medical Oncologist & Section Head of Medical Oncology, Aga Khan University Hospital, NairobiTopic: Early and Locally Advanced HER2 Positive Breast Cancer — Evolving Strategies in Diagnosis, Treatment, and Long-Term Outcomes.

Dr. Angela McligeyoPhysician and Medical OncologistTopic: Metastatic HER2 Positive Breast Cancer — Optimizing Outcomes Through Novel Therapies and Multidisciplinary Care.

Moderator

Dr. Catherine NyongesaDirector of Medical Services, Kenyatta National Hospital & Co-founder, Texas Cancer Centre, Nairobi.

Digital Health: A Breast Cancer Journey
2025-10-21 19:00 - 20:30
Date: 21st October 2025
Time: 7 PM – 8:30 PM (EAT)
CPD Accredited

Moderator:

Dr. Sitna Ali Mwanzi – Consultant Medical Oncologist, Kenyatta National Hospital

Speakers:

Dr. Matiko Riro – Health Economist & CEO, Savannah Global Health Institute (SGHI)Topic: The Role of Data in Health Financing for Oncology – Use case Herceptin SC Access program
Dr. Ngure Nyaga – Healthcare Innovator & Technologist, Savannah InformaticsTopic: Leveraging Digital Solutions, Data & AI to Optimise Patient Outcomes in Oncology
Dr. Gladwell Kiarie – Medical Oncologist, The Nairobi HospitalTopic: Optimising Outcomes in Cancer Care – The Breast Cancer Patient Journey

Advancing Breast Cancer Survivorship Care in Kenya
2025-10-23 19:00 - 20:30
Theme: Evidence, Outcomes & Psychosocial PerspectivesDate: 23rd October 2025Time: 7:00 PM – 8:30 PM EATCPD Accredited
Speakers & Topics:
1. Zahra Haji

Psycho-oncologist & Associate Scientist
Psychosocial Oncology Lead, DART Lead Kenya; Aga Khan University Hospital Nairobi
Topic: The Emotional Journey of Survivorship: Addressing Psychological Well-being after Breast Cancer

2. Prisca Githuka

Vice-Chairperson & Advocacy Chair, Kenyan Network of Cancer Organizations (KENCO); Chairlady, Cancer Survivors Association of Kenya; Founder and Team Leader – Pink Hearts Cancer Support Foundation
Topic: Lived Experience of Breast Cancer Survivors in Kenya: Gaps and Implications for Care

3. Dr. Joyfrida Chepchumba

Pharmacist & Program Officer – Treatment, Palliative Care and Survivorship Pillar, National Cancer Control Program
Topic: Policy Frameworks for Breast Cancer Survivorship Care in Kenya

4. Lyagamula (Gammy) Kisia

Research Officer, African Population and Health Research Center (APHRC), Kenya
Topic: Breast Cancer Survivorship in Kenya: Key Findings from a Pilot Study

Moderator: Dr. Miriam Mutebi

Consultant Breast Surgical Oncologist & Health Systems Researcher, Aga Khan University in Nairobi, Kenya

Organizers & Partners:

KESHO (Kenya Society of Hematology & Oncology)
NCCP (National Cancer Control Programme)
KILELE Health Association
KENCO (Kenyan Network of Cancer Organizations)
APHRC (African Population and Health Research Center)

Multidisciplinary Management of Hepatocellular Carcinoma
2025-10-30 19:00 - 20:30
Multidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited)
Date: 30th October 2025Time: 7:00 PM – 8:30 PM EAT
Moderator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon, Hercules Healthcare
Speakers:

Dr. Gladwell KiarieMedical Oncologist, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends
Dr. Eric MurungaConsultant Physician, Gastroenterologist; Chairman, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings
Dr. Samuel NgukuConsultant, Radiology and Nuclear Medicine, Aga Khan University Hospital, NairobiTopic: Imaging of Hepatocellular Carcinoma

Organized by:Kenya Society of Haematology & Oncology (KESHO)
Partner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
The Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates
Presentations by Dr Gladwell Kiarie and Dr Eric Murunga
Two complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC), with a focus on pragmatic, evidence-based approaches applicable to resource-limited settings.
Dr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma, emphasizing the importance of stage-guided, individualized care. Using established staging frameworks, she highlighted how tumor burden, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies, including immunotherapy and targeted agents, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC.
Dr Eric Murunga addressed the management of chronic Hepatitis B within real-world, resource-constrained contexts. He outlined practical diagnostic pathways, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools, long-term antiviral therapy and structured follow-up. Preventive strategies including screening, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer.
Together, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease, particularly viral hepatitis.
Key takeaway: Strengthening early identification and treatment of chronic Hepatitis B, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma, is central to reducing advanced liver cancer and improving survival in resource-limited settings.

Advances in Small-Cell Lung Cancer Treatment
2025-11-13 19:00 - 20:30
Date: 13th November 2025Time: 7 PM – 8:30 PM EAT

SpeakerDr. Riaz KasmaniMedical Oncologist, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances, Evidence and Clinical Challenges

ModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head, Pulmonology, Aga Khan Hospital

Organized by:KESHOKenya Society of Haematology & Oncology
Supported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
Dr Kasmani presented an overview of Small Cell Lung Cancer (SCLC), focusing on disease biology, treatment response, relapse patterns and emerging research directions.
SCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive, with high response rates to first-line therapy, relapse is common and subsequent responses are often short-lived.
The presentation highlighted current staging approaches, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment, patterns of relapse and the clinical distinction between sensitive and refractory disease, which continues to guide second-line treatment decisions.
Key takeaway: Despite high initial response rates, SCLC remains a challenging disease with frequent relapses, underscoring the need for timely diagnosis, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.
